Clinical Trial Update: Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of imatinib mesylate and docetaxel in non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Imatinib (imatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED